Sorrento, a clinical and commercial stage biopharmaceutical company, completed the acquisition of Virex Health, a biotechnology firm that enables widespread testing in life. Financial terms were not disclosed. “We at Sorrento are amazed by the unmatched sensitivity of the Virex tests for detecting the virus that causes Covid-19 and are excited to mass produce and commercialize the rapid at-home tests for daily Covid-19 testing and frequent early cancer detection,” Henry Ji, Sorrento Chairman and CEO.